typical side effects | CTC grade | end of treatment (N = 14) | 6 weeks post completion of treatment, N = 14 | 4-5 months post completion of treatment, N = 14 |
---|---|---|---|---|
mucositis | I | 2 (14.3%) | 5 (35.7%) | 3 (21.4%) |
II | 8 (57.1%%) | 2 (14.3%) | ||
III | 4 (28.6%) | 0 | ||
dermatitis | I | 2 (14.3%) | 6 (42.9%) | |
II | 6 (42.9%) | 0 | ||
III | 2 (14.3%) | 0 | ||
acneiforme skin rash | I | 5 (35.7%) | 1 (7.1%) | |
II | 9 (64.3%) | 0 | ||
III | 1 (7.1%) | 0 | ||
dysphagia | I | 5 (35.7%) | 4 (28.6%) | |
II | 7 (50%) | 9 (64.3%) | 3 (21.4%) | |
III | 1 (7.1%) | 1 (7.1%) | 1 (7.1%) | |
xerostomia | I | 8 (57.1%) | 9 (64.3%) | 10 (71.4%) |
II | 5 (35.7%) | 2 (14.3%) | 1 (7.1%) |